| Trial ID: | L4392 |
| Source ID: | NCT04215536
|
| Associated Drug: |
Empagliflozin
|
| Title: |
Replication of the EMPAREG Diabetes Trial in Healthcare Claims
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes
|
| Interventions: |
DRUG: Empagliflozin|DRUG: DPP-4 inhibitor
|
| Outcome Measures: |
Primary: Composite outcome of Stroke, MI, and Mortality, Composite outcome of MI, stroke, and mortality - Please refer to uploaded protocol for full definition due to size limitations., Through study completion (a median of 120-140 days) |
|
| Sponsor/Collaborators: |
Sponsor: Brigham and Women's Hospital
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
103752
|
| Study Type: |
OBSERVATIONAL
|
| Study Designs: |
Observational Model: |Time Perspective: p
|
| Start Date: |
2019-07-08
|
| Completion Date: |
2021-02-18
|
| Results First Posted: |
|
| Last Update Posted: |
2023-07-27
|
| Locations: |
Brigham & Women's Hospital, Boston, Massachusetts, 02120, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT04215536
|
